First Patient Dosed With CX-801 Plus Keytruda in Metastatic Melanoma
Source: Cure, May 2025
The first patient has been dosed with CX-801 in combination with Keytruda (pembrolizumab) in an ongoing phase 1 dose escalation study, which is evaluating the safety and initial clinical activity of the agent in patients with metastatic melanoma, according to a news release from CytomX Therapeutics.
Following initial success with CX-801 alone, CytomX has launched the combination arm of a phase 1 trial testing CX-801 with Keytruda in metastatic melanoma
“We are excited to begin evaluating this combination therapy that has the potential to provide significant clinical benefit to patients with PD-1 refractory melanoma, which remains an area of high unmet need,” Dr. Wayne Chu, chief medical officer of CytomX Therapeutics, said in the news release. “Utilizing CytomX’s proprietary conditional activation platform to maintain potency and widen interferon’s therapeutic index, CX-801 is well suited to combine with Keytruda and could become an important component of combination immuno-oncology therapy. We look forward to initial phase 1a translational and biomarker data in advanced melanoma in the second half of 2025.”